GlassScriptPhysician profile
Noa Holoshitz
NPI 1730379017
$5,989.24
in general payments reported to CMS, 2019-2025
19 companies · $519 in 2025
The $519 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,091 · 2020: $491 · 2021: $542 · 2022: $498 · 2023: $344 · 2024: $505 · 2025: $519.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,368.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,367.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,142.06 | 2019-2020 | |
| Edwards Lifesciences Corporation | $1,264.23 | 2019-2025 | Sapien 3 Ultra Resilia |
| Boston Scientific Corporation | $820.68 | 2019-2025 | Watchman Access System, Watchman Flx |
| W. L. Gore & Associates, INC. | $440.17 | 2019-2024 | Gore Cardioform Septal Occluder |
| Abiomed | $400.36 | 2020-2025 | Impella |
| Medtronic, INC. | $363.33 | 2021-2025 | Onyx Frontier, Corevalve Evolut R, Symplicity G3 |
| Medtronic Vascular, INC. | $116.08 | 2019 | |
| Cardiovascular Systems INC. | $109.14 | 2019 | |
| Stryker Corporation | $67.98 | 2025 | Artix Mt |
| Novo Nordisk INC | $63.94 | 2024 | Wegovy, Ozempic |
| Novartis Pharmaceuticals Corporation | $57.20 | 2025 | |
| Shockwave Medical, INC | $32.00 | 2019 | |
| Biotronik INC. | $20.83 | 2025 | Orsiro Mission |
| Livanova USA, INC. | $19.99 | 2019 | |
| Pfizer INC. | $17.92 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medicomp INC | $16.05 | 2024 | Telepatch Cardiac Monitor |
| Terumo Medical Corporation | $13.00 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $12.49 | 2022 | |
| Janssen Pharmaceuticals, INC | $11.79 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Noa Holoshitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.